Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal
Acadia Pharma’s primary strategy over the last few years has been to get its controversial Parkinson’s drug approved for other diseases, including depression and schizophrenia. Now, for the first time in 2 years, the company is adding a new chemical to its pipeline.
Acadia has agreed to a milestone-heavy deal with Vanderbilt University on a program to allosterically target a receptor called muscarinic M1, a potential path toward treating certain central nervous system disorders, including Alzheimer’s and schizophrenia. The deal will pay Vanderbilt $10 million, with $515 million in potential milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.